Prognostic Factors in Metastatic Colorectal Cancer

Prognostic evaluation in metastatic colorectal cancer encompasses a spectrum of clinical, pathological and molecular variables that together inform risk stratification and therapeutic decision-making. Clinically, patient performance status, extent and sites of metastatic spread (liver, lung, peritoneum), and response to prior treatments remain foundational. Pathological features such as tumour differentiation, lymphovascular invasion and number of metastatic lesions further refine risk. At a molecular level, RAS and BRAF mutational status, microsatellite instability, tumour mutational burden and gene expression signatures exert strong influence on survival estimates. Primary tumour location (sidedness) has emerged as an independent prognostic marker, reflecting underlying biological divergences between right- and left-sided disease. Additional layers of prognostic information are derived from the tumour microenvironment, including immune infiltration patterns and angiogenic factor expression. Emerging biomarkers such as circulating tumour DNA and novel immunological signatures offer dynamic assessment of disease burden and residual risk. Integrative prognostic models that combine clinical, radiological and molecular data are increasingly adopted to personalise treatment sequencing and enrolment in clinical trials, thereby optimising outcomes on a patient-by-patient basis.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Prognostic Factors in Metastatic Colorectal Cancer publication trend

The graph below shows the total number of articles in prognostic factors in metastatic colorectal cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Metastatic Colorectal Cancer: Cancer of the colon or rectum that has spread to distant organs beyond the primary site.

Prognostic Factor: A patient or tumour characteristic measured at diagnosis or during treatment that predicts the likely course of the disease.

Sidedness: The anatomical origin of the primary tumour (right colon, left colon or rectum), reflecting distinct biological and clinical behaviour.

Overall Survival (OS): The duration from diagnosis or treatment start until death from any cause.

Progression-Free Survival (PFS): The interval from treatment initiation until disease progression or death, whichever occurs first.

Biomarker: A measurable biological molecule or genetic alteration that indicates normal or pathogenic processes and can inform prognosis or treatment selection.

References

1. Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN). Cancers (2023).
2. Real-World Study to Assess Patterns of Treatment Practices and Clinical Outcomes in Metastatic Colorectal Cancer Patients with RAS Wild-Type Left-Sided Tumours in Canada. Current Oncology (2023).